Copyright
©2013 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Obstet Gynecol. Nov 10, 2013; 2(4): 124-128
Published online Nov 10, 2013. doi: 10.5317/wjog.v2.i4.124
Published online Nov 10, 2013. doi: 10.5317/wjog.v2.i4.124
Criticalities in randomized controlled trials on HIPEC for ovarian cancer
Federico Coccolini, Luca Ansaloni, Marco Lotti, General Surgery Dept., Papa Giovanni XXIII Hospital, 24128 Bergamo, Italy
Davide Corbella, Department of Anesthesiology, Papa Giovanni XXIII Hospital, 24128 Bergamo, Italy
Olivier Glehen, Department of Surgical Oncology, Centre Hospitalier Lyon Sud, 69495 Pierre-Bénite, France
Author contributions: Coccolini F contributed to the study design, literature analysis and paper writing; Corbella D and Lotti M contributed to the literature research, literature analysis and manuscript approval; Ansaloni L and Glehen O contributed equally to the final manuscript editing and approval.
Correspondence to: Federico Coccolini, MD, General Surgery Dept., Papa Giovanni XXIII Hospital, P.zza OMS 1, 24128 Bergamo, Italy. federico.coccolini@gmail.com
Telephone: +39-35-2696464 Fax: +39-35-2674963
Received: December 13, 2012
Revised: January 11, 2013
Accepted: March 23, 2013
Published online: November 10, 2013
Revised: January 11, 2013
Accepted: March 23, 2013
Published online: November 10, 2013
Core Tip
Core tip: Hyperthermic intra-peritoneal chemotherapy techniques are miscellaneous and not yet standardized. Well structured phase III randomized trials among specialized centers are necessary to investigate the efficacy of this therapeutic approach, as well as technical details that may contribute to the standardization of the procedure and limit morbidity and mortality.